Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD3 is a multimeric protein complex expressed on the surface of all mature T lymphocytes. It forms a critical part of the T cell receptor (TCR)/CD3 complex that mediates antigen recognition and signal transduction, triggering T cell activation and immune responses[2][3][5]. "Mature CD3-positive lymphocyte" refers to T cells which have completed maturation in the thymus and are capable of participating in adaptive immunity. CD3 expression defines the T cell lineage and is used as a diagnostic and prognostic marker in hematology and oncology. Therapeutically, CD3 is targeted by immunosuppressive and immunomodulatory antibodies in transplantation and autoimmune disease, and by T cell-engaging antibodies in cancer. The term "mature CD3-positive lymphocyte" is commonly used in immunophenotyping to identify and monitor T cells but is not the canonical name of a molecular target. The correct target is the CD3 protein complex itself[2][3][4].
Antibody-mediated modulation or depletion of T cells (immunosuppression); T cell activation or redirection (e.g., bispecific T cell engager therapy)
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CD3 protein complex (T cell co-receptor) (CD3).